# The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma

> **NCT04017897** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 52 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab)

## Key facts

- **NCT ID:** NCT04017897
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-03
- **Primary completion:** 2022-07
- **Final completion:** 2022-07
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2019-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04017897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04017897, "The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04017897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*